Stocks and Investing Stocks and Investing
Sun, May 11, 2025
[ Last Sunday ] - Yahoo Finance
Inside the Yahoo

Supernus: New Approval Holds Promise Of Increased Growth (SUPN)


Published on 2025-05-11 00:21:02 -
  Print publication without navigation

  • Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a planned Q2 launch. Learn more on SUPN stock here.

Supernus Pharmaceuticals received FDA approval for its new drug, Qelbree, aimed at treating ADHD in pediatric patients aged 6 to 17, marking a significant milestone as it is the company's first new product approval since 2018. The approval is expected to drive growth for Supernus, with Qelbree projected to reach peak sales of $250 million to $300 million annually, contributing to the company's revenue diversification beyond its existing products like Trokendi XR and Oxtellar XR. The drug's unique non-stimulant mechanism and its potential to be used in combination with other ADHD treatments could position Qelbree favorably in the competitive ADHD market, although the company will need to navigate challenges such as market penetration and competition from established players.

Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4755699-supernus-new-approval-holds-promise-of-increased-growth ]